

David G. Pegg, Ph.D., DABT

LECTURES AND SCIENTIFIC PRESENTATIONS:

1. Pegg DG, Hook JB. In vivo maturation and substrate stimulation of renal organic acid transport in the rat. *The Pharmacologist* 1973;15:186.
2. Stickney JL, Pegg DG. Are all species equally sensitive to inhibition of norepinephrine (^3H -1-NE) uptake by ouabain? *Fed Proc, Fed Am Soc Exp Biol* 1975;33:504.
3. Pegg DG, Hewitt WR, Hook JB. Effect of penicillin on uptake and runout of PAH in renal cortical slices from newborn rabbits. *The Pharmacologist* 1974;16:317.
4. Pegg DG, Hook JB. Pharmacodynamic analysis of substrate stimulation of p-aminohippurate transport in newborn rabbit kidney. *Fed Proc, Fed Am Soc Exp Biol* 1975;34:803.
5. Pegg DG Hook JB. Pharmacodynamic analysis of substrate stimulation of p-aminohippurate transport in newborn rabbit kidney. *Am Fed Clin Res* 1975. E. Lansing, MI.
6. Hook JB, Bowman HM, Ecker JL, Hewitt WR, Hirsch GH, Pegg DG. Influence of environmental stresses on functional maturation of renal organic anion transport. *West Pharmacol Soc* 1975. Honolulu, Hawaii.
7. Pegg DG, Hook JB, Bernstein J. Biochemical and ultrastructural correlates of substrate stimulation of renal organic anion transport. *Midwest Pharmacol Soc* 1975. Ann Arbor, MI.
8. Hook JB, Pegg DG, Bernstein J. Biochemical and ultrastructural correlates of substrate stimulation of renal organic anion transport. *Sixth International Congress of Pharmacol* 1975. Helsinki, Finland.
9. Hewitt WR, Pegg DG, Hook JB. Transport specificity of stimulation of neonatal rabbit renal organic anion transport. *Am Soc Nephrol* 1975. Washington, D.C.
10. Pegg DG, Hewitt WR, McCormack KM, Hook JB. The effect of TCDD intoxication on renal function in the rat. *Am Fed Clin Res* 1975. Eloise, MI.
11. Pegg DG, Hook JB. Glutathione-S-Aryltransferase and organic anion transport in rat kidney. *Fed Proc, Fed Am Soc Exp Biol* 1976;35:224.

LECTURES AND SCIENTIFIC PRESENTATIONS: (cont.)

12. Pegg DG, Zempel JA, Braun WH, Gehring PJ. Disposition of (¹⁴C) tetrachloroethylene following oral and inhalation exposure in rats. Society of Toxicology, 17th Annual Meeting, March 12-16, 1978. San Francisco, CA.
13. Soderholm SC, Pegg DG. A versatile, small-volume nebulizer. Twelfth Aerosol Technology Meeting, August 27-29, 1979. Warren, MI.
14. Pegg DG. Toxicity and biologic fate of di-2-ethylhexyl phthalate following inhalation exposure in rats. Society of Toxicology 19th Annual Meeting, March 9-13, 1980. Washington, D.C.
15. Pegg DG. Toxicity and fate of di-isodecyl phthalate following inhalation exposure in rats. *The Toxicologist* 1981;1(1):54.
16. Pegg DG. Disposition of di-2-ethylhexyl phthalate following oral and inhalation exposure in rats. Michigan Regional Section of the Society of Toxicology, Toxicology in Michigan Today, May 8, 1981. E. Lansing, MI.
17. Pegg DG. Disposition of di-isodecyl phthalate following oral exposure in rats. *The Toxicologist* 1982;2(1):166.
18. Pegg DG, White HJ. Peroxisome proliferation in rats fed di-2-ethylhexyl and di-isodecyl phthalates. *The Pharmacologist* 1982;24(3):149.
19. Pegg DG. Effect of dose on di-isodecyl phthalate disposition in rats. *The Toxicologist* 1983;3(1):50.
20. Pegg DG, Chan TL, Strom KA, White HJ. Deposition, retention, and clearance of inhaled particles and gases. Michigan Regional Chapter, Society of Toxicology. Symposium on Inhalation Toxicology, November 11, 1983. Ann Arbor, MI.
21. Fitzgerald J, Pegg D, Jayasekara U, et al. Preliminary toxicologic evaluation of CI-926, a new antihypertension agent. *The Toxicologist* 1985;5:8.
22. Figueroa IC, Pegg DG, Kim SN, de la Iglesia FA. Assessment of methodology for determining acute cardiotoxic potential of anticancer drugs. *The Toxicologist* 1986;6(1):199.
23. Pegg DG, Kim SN. Acute intravenous toxicity of CI-937, an anthrapyrazole anticancer drug candidate. *The Toxicologist* 1986;6(1):300.

LECTURES AND SCIENTIFIC PRESENTATIONS: (cont.)

24. Kropko ML, McGuire EJ, Pegg DG. Genotoxicity of selenazofurin, a potential anticancer agent. *The Toxicologist* 1986;6(1):266.
25. Pegg D, Goldenthal E. Acute toxicity of fostriecin, a novel anticancer antibiotic, in mice and rats. *The Pharmacologist* 1986;28(3):210.
26. Paradiso L, Kim S, Pegg D. Toxicity evaluation of CI-937, an anthrapyrazole anticancer agent, in rats. *The Pharmacologist* 1986;28(3):209.
27. Kim SN, Pegg DG, de la Iglesia FA. Cardiotoxicity of CI-937, an anthrapyrazole anticancer candidate drug, in rats. *J Mol Cellular Cardiology* 1986;18(3):39.
28. Theiss JC, Kropko ML, Pegg DG. Genotoxicity assessment of two topoisomerase II inhibitors, CI-937 and CI-920 (fostriecin). *Proceedings of the American Association for Cancer Research* 1987;28:441.
29. Pegg DG, Watkins JR. Subacute intravenous toxicity of CI-937, an anthrapyrazole anticancer drug candidate, in beagle dogs. *The Toxicologist* 1987;7(1):207.
30. Pegg DG, Watkins JR. Subchronic intravenous toxicity of amsacrine, an anticancer chemotherapeutic compound, in rats. *The Toxicologist* 1988;8(1):256.
31. Pegg DG, Walsh KM. Intravenous toxicity of CI-935, an anticancer drug candidate, in rats. *The Toxicologist* 1989;9(1):112.
32. Susick RL, Hawkins KL, Pegg DG. Acute nephrotoxicity of fostriecin, a novel anticancer antibiotic, in rats. *The Toxicologist* 1989;9(1):174.
33. MacDonald JR, Morse CC, Pegg DG. Leucovorin protection against trimetrexate toxicity in rats. *The Toxicologist* 1989;9(1):199.
34. Susick RL, Dominick MA, Pegg DG. Renal function and structure in dogs following treatment with the ACC inhibitor quinapril. *The Toxicologist* 1990;10(1):268.
35. MacDonald JR, Morse CC, Pegg DG. Trimetrexate toxicity in rats: protection by leucovorin. *The Toxicologist* 1990;10(1):281.
36. Verneti LA, Wolfgang GHI, MacDonald JR, Dominick MA, Pegg DG. Cytotoxicity of PD132301-2 in guinea pig adrenocortical cell cultures. *The Toxicologist* 1992;12(1):133.
37. Wolfgang GHI, Dominick MA, Pegg DG. Comparative nephrotoxicity of CI-973, cisplatin and carboplatin in male wistar rats. *The Toxicologist* 1992;12(1):430.

LECTURES AND SCIENTIFIC PRESENTATIONS: (cont.)

38. Verneti LA, Wolfgang GHI, MacDonald JR, Dominick MA, Pegg DG. ATP depletion is associated with cytotoxicity of a novel lipid regulator in guinea pig adrenocortical cells. Michigan Chapter of the Society of Toxicology 1992.
39. Leibbrandt MEI, Wolfgang GHI, Walsh KM, Pegg DG. The role of apoptosis and specific gene expression in cisplatin-induced nephrotoxicity in rats. Proc. International Congress Toxicol. VII. 1995.
40. Pegg DG. Toxicology in Drug Development. Invited lecture in Chm 412- Toxicology II at Eastern Michigan University, April 18, 1995.
41. Pilcher G, Breider M, Pegg D. Single-dose intravenous toxicity of CI-1010, a cytotoxic radiosensitizing nitroimidazole derivative, in rats. The Toxicologist 1996;30(1):103.
42. Breider MA, Ulloa HM, Pegg DG, Gough AW, Gragtmans B. Ocular toxicity in cynomolgus monkeys treated with CI-1010, A 2-nitro-imidazole radiosensitizer. The Toxicologist 1997;36(1):45.
43. Pilcher G, Graziano M, Breider M, Pegg D. 3-week intravenous toxicity of CI-1010, a cytotoxic radiosensitizing nitroimidazole, in rats. The Toxicologist 1997;36(1):181.
44. Pegg DG. Toxicology in Drug Development. Invited lecture in Chm 412- Toxicology II at Eastern Michigan University, April 21, 1998.
45. Pegg DG. Organizer and co-chair of a symposium on second-tier testing in safety pharmacology. 6th Annual Meeting of the General Pharmacology/Safety Pharmacology Discussion Group, Philadelphia, PA, October 5-6, 1998.
46. Krishna G, Urda G, Garvin J, Pegg D. Genotoxicity assessment of suramin- a potential drug for prostate cancer. The Toxicologist 1999;48(1-S):122.
47. Dethloff LA, Pegg DG, Metz AL. Preclinical toxicity studies of the phospho-diesterase IV inhibitor CI-1018 in rats. The Toxicologist 1999;48(1-S):318.
48. Pegg DG, Dethloff LA, Walsh KM. Preclinical toxicology profile of CI-1012 in rats. The Toxicologist. 1999;48(1-S):318.
49. Pegg DG. Toxicology in Drug Development. Invited lecture in Chm 412- Toxicology II at Eastern Michigan University, April 13, 1999.
50. Pegg DG. The PhRMA database in support of toxicology testing for the exploratory IND. Invited speaker. Toxicology Forum – Summer Meeting, Aspen, CO. July 19 – 22, 2004.

LECTURES AND SCIENTIFIC PRESENTATIONS: (cont.)

51. Pegg DG, The PhRMA database in support of toxicology testing for the exploratory IND. Invited speaker. PhRMA Conclave, Bethesda, MD. December 1, 2004.
52. Pegg DG, The PhRMA Database in support of toxicology testing for the exploratory IND. Invited speaker. International Conference on Drug Development, Austin, TX. February 16, 2005.
53. Pegg DG, Grzemeski F, Management of drug in control samples from a topical development program. Invited speaker. PhRMA Preclinical Leadership Committee Meeting, Bethesda, MD. June 23-24, 2005.
54. Pegg DG. Research and Development of Pharmaceutical Agents. Invited speaker. Michigan State University Short Course on Integrative Pharmacology/Toxicology, East Lansing, MI. August 11, 2005.
55. Pegg DG. Symposium Chair – Mode of action associated with induction of endothelial cell tumors – hemangiosarcoma, 45th Annual Meeting of the Society of Toxicology, San Diego, CA. March 5-9, 2006.
56. Pegg DG. Epigenetic mode of action associated with induction of hemangiosarcoma in mice. Symposium speaker. 45th Annual Meeting of the Society of Toxicology, San Diego, CA. March 5-9, 2006.
57. Pegg DG and Bailie MB. Enabling technologies for key-decision-making in early clinical testing and case studies from pfizer's experience with exploratory INDs. 6th Annual Meeting of the Safety Pharmacology Society, San Diego, CA. September 27, 2006.
58. Pegg DG. Enabling technologies for key decision-making in early clinical trials. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Antonio, TX. October 28, 2006.
59. Pegg DG. Risk management in development of novel pharmaceutical agents. Wayne State University Department of Pharmaceutical Sciences Seminar Series. Detroit, MI. November 2, 2006.
60. Pegg DG. Innovative approaches to nonclinical development and risk management of novel pharmaceutical agents. University of Michigan Medical School, Department of Pharmacology, Ann Arbor, MI. January 10, 2007.
61. Pegg DG. Epigenetic mode of action associated with induction of hemangiosarcoma in mice. 19th Annual Euro Meeting of the Drug Information Association, Vienna, Austria. March 26-28, 2007

62. Pegg DG. Enabling technologies for key decision-making in early clinical trials. 2nd Joint Annual Meeting of AGAH Germany and Club Phase 1 (France) - Positioning Human Pharmacology for the Future, Bad Homburg v.d.H., Germany, April 26 – 27, 2007.

PUBLICATIONS:

1. Pegg DG, Hewitt WR, Hook JB. Substrate stimulation of p-aminohippuric acid transport: Effect on uptake and runout. *Proc Soc Exp Biol Med* 1975;149:546-549.
2. Pegg DG, Hook JB. Disappearance of p-aminohippurate and inulin from plasma of newborn and adult rats. *Biol Neonate* 1975;27:108-114.
3. Hook JB, Bowman HM, Ecker JL, Hewitt WR, Hirsch GH, Pegg DG. Influence of environmental stresses on functional maturation of renal organic anion transport. *Proc West Pharmacol Soc* 1975;18:344-347.
4. Pegg DG, Hook JB. Pharmacodynamic analysis of substrate stimulation of p-aminohippurate transport in newborn rabbit kidney. *J Pharmacol Exp Ther* 1975;195:16-21.
5. Pegg DG, Bernstein J, Hook JB. Biochemical and ultrastructural correlates of substrate stimulation of renal organic anion transport. *Proc Soc Exp Biol Med* 1976;151:720-725.
6. Pegg DG, Hewitt WR, Hook JB. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on renal function in the rat. *J Toxicol Env Hlth* 1976;2:55-65.
7. Pegg DG, Hook JB. Glutathione S-transferase: an evaluation of their role in renal organic anion transport. *J Pharmacol Exp Ther* 1977;200:65-74.
8. Pegg DG, McCormack K, Hook JB. Effect of substrate pretreatment on renal organic anion transport in the adult rat. *Experientia* 1976;32:1315-1316.
9. Watanabe PG, Zempel JA, Pegg DG, Gehring PJ. Hepatic macromolecular binding following exposure to vinyl chloride. *Toxicol Appl Pharmacol* 1978;44:571-579.
10. Pegg DG, Zempel JA, Braun WH, Watanabe PG. Disposition of (¹⁴C) tetrachloroethylene following oral and inhalation exposure in rats. *Toxicol Appl Pharmacol* 1979;51:465-474.
11. Pegg DG, Soderholm SC. An apparatus for production of submicron radiolabelled di-2-ethylhexyl phthalate aerosol. *Am Ind Hyg Assoc J* 1982;43:333-337.
12. Hook JB, Hewitt WR, Pegg DG, Stroo WE. Studies on the mechanism of substrate stimulation of renal organic anion transport in newborn rabbits. In: Spitzer A, ed. *The kidney during development: Morphology and function*. New York: Nasson Publishing Co., Inc., 1982:345-353.
13. Susick RL, Hawkins KL, Pegg DG. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic. *Fundam Appl Toxicol* 1990;15:258-269.

PUBLICATIONS: (cont.)

14. MacDonald JR, Susick RL, Pegg DG, Dominick MA. Renal structure and function in rats following suprapharmacologic doses of an angiotensin converting enzyme inhibitor. *J. Cardiovascular Pharmacol.* 1992;19:282-289.
15. Verneti LA, MacDonald JR, Wolfgang GHI, Dominick MA, Pegg DG. ATP depletion is associated with cytotoxicity of a novel lipid regulator in guinea pig adrenocortical cells. *Toxicol. Appl. Pharmacol.* 1993;118:30-38.
16. Whitfield L, Pegg D. Toxicokinetics of Anticancer Compounds. In: *Toxicokinetics.* Welling P and delalglesia F, eds. Marcel Dekker. New York. 1993. pp. 267-289.
17. MacDonald JR, Pegg DG. Extravasation Injury Potential of CI-980, a Novel Synthetic Mitotic Inhibitor. *Cancer Chemotherapy and Pharmacology.* 1993;32:365-367.
18. MacDonald JR, Courtney CL, Pegg DG. Leucovorin protection against repeated daily dose toxicity of trimetrexate in rats. *Fundamen. Appl. Toxicol.* 1993;21:244-252.
19. Graziano MJ, Dethloff LA, Griffin G, Pegg DG. Effects of the angiotensin-converting enzyme inhibitor quinapril on renal function in rats. *Arch. int. Pharmacodyn. Ther.* 1993;324:87-104.
20. Wolfgang GHI, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG. Comparative nephrotoxicity of a novel platinum compound, cisplatin and carboplatin in male Wistar rats. *Fundam. Appl. Toxicol.* 1994;22:73-79.
21. Susick RL, Dominick MA, Ulloa HM, Pegg DG. Renal morphology and function in dogs following treatment with the angiotensin converting enzyme inhibitor quinapril. *J. Cardiovascular Pharmacol.* 1994;23(2):275-282.
22. Wolfgang GH, MacDonald JR, Verneti LA, Pegg DG, Robertson DG. Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase. *Life Sciences.* 1995;56(13):1089-1093.
23. Verneti LA, MacDonald JR, Pegg DG. Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures. *Toxicology In Vitro.* 1996;10:51-57.
24. McGuire EJ, Anderson JA, Gough AW, Pegg DG, Theiss JC de la Iglesia FA. Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). *J. Toxicol. Sciences.* 1996;21:207-214.

PUBLICATIONS: (cont.)

25. Pegg, DG, Watkins JR, Graziano MJ, McKenna MJ. Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male wistar rats. *Fundam. Appl. Toxicol.* 1996;32:45-52.
26. Graziano MJ, Courtney CL, Meierhenry, EF, Kheoh T, Pegg DG, Gough AW. Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in wistar rats. *Fundam. Appl. Toxicol.* 1996;32:53-65.
27. Fitzgerald AL, Juneau P, Alvey J, Lazaroff LM, Pegg DG. Characterization of histaminergic response to intravenous CI-1010, a nitroimidazole radiosensitizer in beagle dogs using a cross-over design. *Toxicology Methods.* 1998;8:105-115.
28. Breider MA, Ulloa HM, Pegg DG, Gough AL. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. *Toxicologic Pathol.* 1998;26(5):651-656.
29. Pegg DG, Duddy SK. Establishing a mode of action for hemangiosarcoma induction in pregabalin-treated mice: Outline of mechanistic research and a framework for human relevance. *Toxicol. Sciences* (in preparation)
30. Pegg DG, Bleavins M, Herman J, Wojcinski Z, Graziano M, Henck J, Anderson TD, Duddy SK. Induction of hemangiosarcoma in mice given the $\alpha_2\delta$ agonist, pregabalin: Analysis of genotoxicity, carcinogenicity and tumor genetics. *Toxicol. Sciences* (in preparation).
31. Criswell K, Olsen E, Bailie M, Pegg D, Wojcinski Z, Anderson T. Pregabalin alters respiration and induces a mixed acid-base disorder in B6C3F1 mice and Wistar rats. *Toxicol. Sciences* (in preparation).
32. Criswell K, Pegg D, Wojcinski Z, Anderson T. Pregabalin, an $\alpha_2\delta$ agonist, increases erythropoiesis, megakaryopoiesis and macrophage production in mouse bone marrow and spleen. *Toxicol. Sciences* (in preparation).
33. Criswell K, Pegg D, Wojcinski Z, Rahbari R, Albassam M, Herman J, Duddy S, Anderson T. Pregabalin alters peripheral blood platelet function and promotes endothelial and kupffer cell proliferation in B6C3F1 mouse liver. *Toxicol. Sciences* (in preparation).
34. Wojcinski Z, Criswell K, Herman J, Anderson T, Wesche D, Giddings J, Abel R, Duddy S, Pegg D. Mode of action associated with induction of hemangiosarcoma in mice given the $\alpha_2\delta$ agonist, pregabalin, and assessment of human relevance. *Toxicol. Sciences* (in preparation)